Full results & analysis
Available in the Gosset platform where reported.
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing CT-P63 and CT-P66 with Placebo (2 arms). Primary endpoint: Time to clinical recovery at Day 14. Planned start Apr 2022; status: withdrawn.
02
Design
2 arms- Study design
- RandomizedDouble-blind
CT-P63 and CT-P66
Inhaled CT-P63 and CT-P66 combination therapy
Placebo
Inhaled Placebo
03
Who it enrols
Adult patients with confirmed SARS-CoV-2 infection, oxygen saturation ≥ 94% on room air, not requiring supplemental oxygen, and symptom onset within 7 days. Excludes patients with severe pneumonia, requiring hospitalization or supplemental oxygen, or recent use of prohibited antivirals or immunomodulators.
04
Endpoints
Primary
Time to clinical recovery
Secondary
Overall safety
Beyond the preview
Go deeper on NCT05224856.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05224856.